Outcome of Board Meeting held on May 23, 2026.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India reported strong FY2026 standalone revenue of INR 16,755.67 million, up 87% from INR 8,958.99 million in FY2025. Standalone PAT grew 122% to INR 1,613.96 million from INR 726.74 million. Consolidated revenue was INR 23,654.55 million (up 65%) and consolidated PAT was INR 2,221.99 million (up 39%). The Board approved a dividend of INR 1.5 per share (15% on face value), reappointed internal and cost auditors, and received resignation of Deputy CFO Mr. Vishal Thakkar. Key strategic items include proposed acquisition of up to 74.20% stake in listed Bliss GVS Pharma Limited and issuance of 16,000 NCDs worth INR 160 crore. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated financial results. The company also completed acquisition of US-based Jayhawk Fine Chemicals Corporation for USD 150 million in February 2026.
The company delivered exceptional double-digit revenue and PAT growth driven by the Jayhawk acquisition. The proposed Bliss GVS Pharma acquisition signals continued M&A strategy for expansion. The INR 160 crore NCD issuance will increase debt levels. Shareholders receive INR 1.5 per share dividend. Resignation of Deputy CFO may raise minor governance concerns.